Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Regions Hospital
mi
from
Saint Paul, MN
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Regions Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial
Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial
Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Scripps Clinic
mi
from
La Jolla, CA
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
University of California-Davis
mi
from
Sacramento, CA
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
University of Miami
mi
from
Miami, FL
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
University of Louisville
mi
from
Louisville, KY
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Liver Institute of Virginia
mi
from
Newport News, VA
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Liver Institute of Virginia
mi
from
Newport News, VA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Hunter Holmes McGuire VA Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
University of Washington; Harborview Medical Center
mi
from
Seattle, WA
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
University of Washington; Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
University of Birmingham
mi
from
Birmingham,
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
University of Birmingham
mi
from
Birmingham,
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Minnesota Gastroenterology, P.A.
mi
from
Saint Paul, MN
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Minnesota Gastroenterology, P.A.
mi
from
Saint Paul, MN
Click here to add this to my saved trials
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated:  12/31/1969
St. Louis University
mi
from
Saint Louis, MO
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis
Status: Enrolling
Updated: 12/31/1969
St. Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life
A Pragmatic Randomized Controlled Trial to Evaluate the Impact of HealthPROMISE Platform on Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life
A Pragmatic Randomized Controlled Trial to Evaluate the Impact of HealthPROMISE Platform on Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Corticosteroids With Vedolizumab in Crohn's Disease
Corticosteroids as Co-Induction Agents With Vedolizumab in Crohn's Disease: a Double-blind Placebo Controlled Randomized Trial
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Corticosteroids With Vedolizumab in Crohn's Disease
Corticosteroids as Co-Induction Agents With Vedolizumab in Crohn's Disease: a Double-blind Placebo Controlled Randomized Trial
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Web-based Management of Pediatric Functional Abdominal Pain
Predicting Treatment Outcomes in Pediatric Functional Abdominal Pain
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Web-based Management of Pediatric Functional Abdominal Pain
Predicting Treatment Outcomes in Pediatric Functional Abdominal Pain
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Children's Hospital
mi
from
Nashville, TN
Click here to add this to my saved trials
Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
Compassionate Use of an Intravenous Fish Oil Lipid Emulsion (Omegaven®) for the Treatment of Intestinal Failure Associated Liver Disease in Children
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital & Medical Center
mi
from
Omaha, NE
Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children
Compassionate Use of an Intravenous Fish Oil Lipid Emulsion (Omegaven®) for the Treatment of Intestinal Failure Associated Liver Disease in Children
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital & Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Fecal Microbiota Transplant (FMT) in Pediatric Active Crohn's Colitis
A Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Crohn's Colitis
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Fecal Microbiota Transplant (FMT) in Pediatric Active Crohn's Colitis
A Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Crohn's Colitis
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis
A Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis
A Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Longitudinal Prospective Outcomes Study of Laparoscopic Abdominal Wall Hernia Repair Using Symbotex™ Composite Mesh
A Longitudinal Prospective Outcomes Study of Laparoscopic Abdominal Wall Hernia Repair Using Symbotex™ Composite Mesh
Status: Enrolling
Updated:  12/31/1969
Anne Arundel Medical Center
mi
from
Annapolis, MD
A Longitudinal Prospective Outcomes Study of Laparoscopic Abdominal Wall Hernia Repair Using Symbotex™ Composite Mesh
A Longitudinal Prospective Outcomes Study of Laparoscopic Abdominal Wall Hernia Repair Using Symbotex™ Composite Mesh
Status: Enrolling
Updated: 12/31/1969
Anne Arundel Medical Center
mi
from
Annapolis, MD
Click here to add this to my saved trials
Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults
Impact of Almond Supplementation, Relative to a Low-fat, High Carbohydrate Control, on Body Composition in Overweight and Obese Black and Hispanic Adults
Status: Enrolling
Updated:  12/31/1969
New York Nutrition Obesity Research Center
mi
from
New York, NY
Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults
Impact of Almond Supplementation, Relative to a Low-fat, High Carbohydrate Control, on Body Composition in Overweight and Obese Black and Hispanic Adults
Status: Enrolling
Updated: 12/31/1969
New York Nutrition Obesity Research Center
mi
from
New York, NY
Click here to add this to my saved trials
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated:  12/31/1969
Stanford Center for Clinical & Translational Research & Education
mi
from
Palo Alto, CA
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated: 12/31/1969
Stanford Center for Clinical & Translational Research & Education
mi
from
Palo Alto, CA
Click here to add this to my saved trials
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated:  12/31/1969
Gastro Health
mi
from
Miami, FL
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated: 12/31/1969
Gastro Health
mi
from
Miami, FL
Click here to add this to my saved trials
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated:  12/31/1969
Carle Foundation, Center for Digestive and Liver Disease
mi
from
Urbana, IL
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated: 12/31/1969
Carle Foundation, Center for Digestive and Liver Disease
mi
from
Urbana, IL
Click here to add this to my saved trials
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Associates of Tidewater
mi
from
Chesapeake, VA
Click here to add this to my saved trials
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Assocaites of Central Georgia
mi
from
Macon, GA
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Assocaites of Central Georgia
mi
from
Macon, GA
Click here to add this to my saved trials
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated:  12/31/1969
Great Lakes Gastroenterology Research
mi
from
Mentor, OH
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome
Status: Enrolling
Updated: 12/31/1969
Great Lakes Gastroenterology Research
mi
from
Mentor, OH
Click here to add this to my saved trials
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects
Status: Enrolling
Updated:  12/31/1969
New Orleans Center for Clinical Research
mi
from
Knoxville, TN
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects
Status: Enrolling
Updated: 12/31/1969
New Orleans Center for Clinical Research
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Digestive Health Specialists of the Southeast
mi
from
Dothan, AL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Southern California Research Institute Medical Group Inc
mi
from
Los Angeles, CA
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Southern California Research Institute Medical Group Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Connecticut Clinical Research Foundation
mi
from
Bristol, CT
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Connecticut Clinical Research Foundation
mi
from
Bristol, CT
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Consultants for Clinical Research of South Florida
mi
from
Boynton Beach, FL
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Consultants for Clinical Research of South Florida
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Sunrise Medical Research
mi
from
Lauderdale Lakes, FL
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Sunrise Medical Research
mi
from
Lauderdale Lakes, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Pharmax Research Clinic
mi
from
Miami, FL
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Pharmax Research Clinic
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
University of Louisville
mi
from
Louisville, KY
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Institute of Michigan,
mi
from
Chesterfield, MI
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Institute of Michigan,
mi
from
Chesterfield, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Center for Digestive Health
mi
from
Troy, MI
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Center for Digestive Health
mi
from
Troy, MI
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Gastrointestinal Associates, P.A.
mi
from
Jackson, MS
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Gastrointestinal Associates, P.A.
mi
from
Jackson, MS
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Nyu Langone Long Island Clinical Research Associates
mi
from
Great Neck, NY
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Nyu Langone Long Island Clinical Research Associates
mi
from
Great Neck, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Consultants for Clinical Research Inc.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
Digestive Health Specialist of Tyler
mi
from
Pasadena, TX
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
Digestive Health Specialist of Tyler
mi
from
Pasadena, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis
A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 12/31/1969
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials